Corbus CRB-701 Phase 1 Western data: low neuropathy, HNSCC responses, dose optimization started

Corbus Pharmaceuticals Holdings, Inc.

No DLTs; peripheral neuropathy 5% (Grade 1-2) vs 3% in China; combined 4% across 75 patients.
Ocular AEs lower in Western study (38% vs 66%) with proactive prevention protocol at 2.7/3.6 mg/kg.
Efficacy: 4 PR in HNSCC (n=7); 1 CR in cervical; mUC responses despite prior EV treatment.
PK comparable to China; CRB-701 shows longer ADC half-life and lower free-MMAE vs enfortumab vedotin.
Dose optimization randomized at 2.7 and 3.6 mg/kg Q3W in HNSCC, cervical, and mUC cohorts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.